Related Experiment Video
Updated: May 18, 2026
10:16
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Treatment options for lysosomal storage disorders: developing insights.
Carin M van Gelder1, Audrey A M Vollebregt, Iris Plug
1Erasmus MC University Medical Center, Center for Lysosomal and Metabolic Diseases, Department of Paediatrics, Dr. Molewaterplein 60, Rotterdam, The Netherlands.
Expert Opinion on Pharmacotherapy
|September 27, 2012
Summary
Lysosomal storage disorders (LSDs) are progressive genetic conditions. Current therapies improve patient outcomes but are not fully curative, necessitating further research for complete cures.
Area of Science:
- Biochemistry
- Genetics
- Medical Research
Background:
- Lysosomal storage disorders (LSDs) are a group of progressive genetic diseases characterized by the accumulation of macromolecules within lysosomes.
- These disorders lead to severe symptoms and premature death, highlighting the urgent need for effective treatments.
Purpose of the Study:
- To provide a comprehensive overview of current and emerging therapeutic strategies for LSDs.
- To discuss the pathophysiology, applications, and limitations of various treatment modalities.
Main Methods:
- Review of current literature on lysosomal storage disorders and their treatments.
- Focused overview of enzyme-replacement therapy, stem-cell therapy, gene therapy, chaperone therapy, and substrate-reduction therapy.
- Discussion of challenges and future prospects in LSD treatment.
Main Results:
- Significant progress has been made in managing LSDs, improving patient outcomes.
- Current treatments, while beneficial, do not offer complete cures for all patients.
- Challenges include efficient tissue targeting (especially the central nervous system), achieving adequate therapeutic levels, and high treatment costs.
Conclusions:
- Further elucidation of the pathways from genetic mutation to clinical symptoms is crucial.
- Development of novel and ultimately curative therapies for LSDs is a key future direction.
- Continued research is essential to overcome treatment limitations and achieve complete disease reversal.
Related Concept Videos
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:31Lysosomes
Lysosomes are membrane-enclosed spherical sacs derived from the Golgi apparatus. The most important function of the lysosome is degrading macromolecules and biological polymers that are released during membrane trafficking events such as the secretory, endocytic, autophagic, and phagocytic pathways. The degradation is carried out by several hydrolytic enzymes active in an acidic environment of the lysosomal lumen. These acid hydrolases are involved in cellular processes such as cell signaling,...
01:31Lysosomes
Lysosomes are membrane-enclosed spherical sacs derived from the Golgi apparatus. The most important function of the lysosome is degrading macromolecules and biological polymers that are released during membrane trafficking events such as the secretory, endocytic, autophagic, and phagocytic pathways. The degradation is carried out by several hydrolytic enzymes active in an acidic environment of the lysosomal lumen. These acid hydrolases are involved in cellular processes such as cell signaling,...
01:27Protein Import into the Peroxisomes
Cells contain membrane-bound organelles called peroxisomes that oxidize organic molecules by transferring hydrogen atoms to oxygen, producing hydrogen peroxide. Peroxisomes enzymatically convert the released hydrogen peroxide into water and oxygen.
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
Peroxisomal Protein Import:
Peroxisomes lack the genetic machinery required to code for their own proteins. Hence, most peroxisomal membrane, lumenal and transmembrane proteins are synthesized in the cytoplasm or ER and transported to the peroxisome...
01:36Delivery Pathways to the Lysosome
Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...